Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-HIPEC trial of sequential paclitaxel and oxaliplatin HIPEC followed by XELOX plus sintilimab in HER2-negative gastric cancer with peritoneal metastasis
ChiCTR2500097205Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sintilimab, oxaliplatin, paclitaxel and capecitabine, sponsored by Sun Yat-sen University Cancer Center. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
sintilimaboxaliplatinpaclitaxelcapecitabine
Beyond the preview
Go deeper on ChiCTR2500097205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097205.